Home
>
National Drug Code (NDC)
>
SEREVENT
SEREVENT - 0173-0521-00 - (salmeterol xinafoate)
Drug Information of SEREVENT
| Product NDC: | 0173-0521 |
| Proprietary Name: | SEREVENT |
| Non Proprietary Name: | salmeterol xinafoate |
| Active Ingredient(s): | 50 ug/1 & nbsp; salmeterol xinafoate |
| Administration Route(s): | ORAL; RESPIRATORY (INHALATION) |
| Dosage Form(s): | POWDER, METERED |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of SEREVENT
| Product NDC: | 0173-0521 |
| Labeler Name: | GlaxoSmithKline LLC |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA020692 |
| Marketing Category: | NDA |
| Start Marketing Date: | 19971125 |
Package Information of SEREVENT
| Package NDC: | 0173-0521-00 |
| Package Description: | 60 POWDER, METERED in 1 INHALER (0173-0521-00) |
NDC Information of SEREVENT
| NDC Code | 0173-0521-00 |
| Proprietary Name | SEREVENT |
| Package Description | 60 POWDER, METERED in 1 INHALER (0173-0521-00) |
| Product NDC | 0173-0521 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | salmeterol xinafoate |
| Dosage Form Name | POWDER, METERED |
| Route Name | ORAL; RESPIRATORY (INHALATION) |
| Start Marketing Date | 19971125 |
| Marketing Category Name | NDA |
| Labeler Name | GlaxoSmithKline LLC |
| Substance Name | SALMETEROL XINAFOATE |
| Strength Number | 50 |
| Strength Unit | ug/1 |
| Pharmaceutical Classes | Adrenergic beta2-Agonists [MoA],beta2-Adrenergic Agonist [EPC] |
